Gilteritinib + Cytarabine + Mitoxantrone + Etoposide + G-CSF + Fludarabine
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
AML With FLT3 Mutation
Conditions
AML With FLT3 Mutation
Trial Timeline
Oct 25, 2017 → Mar 31, 2026
NCT ID
NCT03182244About Gilteritinib + Cytarabine + Mitoxantrone + Etoposide + G-CSF + Fludarabine
Gilteritinib + Cytarabine + Mitoxantrone + Etoposide + G-CSF + Fludarabine is a phase 3 stage product being developed by Astellas Pharma for AML With FLT3 Mutation. The current trial status is active. This product is registered under clinical trial identifier NCT03182244. Target conditions include AML With FLT3 Mutation.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03182244 | Phase 3 | Active |
Competing Products
20 competing products in AML With FLT3 Mutation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY3461767 + Placebo | Eli Lilly | Phase 1 | 33 |
| Glucagon + Insulin | Abvance Therapeutics | Phase 1 | 25 |
| CT-P41 + US-licensed Prolia | Celltrion | Phase 3 | 77 |
| Letrozole | Chugai Pharmaceutical | Phase 2 | 52 |
| Letrozole | Chugai Pharmaceutical | Phase 2 | 52 |
| Letrozole | Chugai Pharmaceutical | Phase 2 | 52 |
| Moderate-intensity statin monotherapy + Ezetimibe or ezetimibe-statin combination therapy | Yuhan | Pre-clinical | 23 |
| PLX3397 + Temozolomide | Daiichi Sankyo | Phase 1/2 | 41 |
| DS-5565 + Pregabalin + Placebo tablet + Placebo capsule | Daiichi Sankyo | Phase 3 | 77 |
| Trastuzumab deruxtecan | Daiichi Sankyo | Phase 2 | 52 |
| DS-5565 | Daiichi Sankyo | Phase 3 | 77 |
| Trastuzumab deruxtecan | Daiichi Sankyo | Phase 2 | 52 |
| Pravastatin | Daiichi Sankyo | Pre-clinical | 23 |
| DS-5565 + Pregabalin + Placebo tablet + Placebo capsule | Daiichi Sankyo | Phase 3 | 77 |
| Quizartinib Dihydrochloride | Daiichi Sankyo | Pre-clinical | 23 |
| DS-5565 + Pregabalin + Placebo tablet + Placebo capsule | Daiichi Sankyo | Phase 3 | 77 |
| CS-3150 | Daiichi Sankyo | Phase 3 | 77 |
| roxadustat | Astellas Pharma | Phase 3 | 77 |
| roxadustat | Astellas Pharma | Phase 3 | 77 |
| tacrolimus | Astellas Pharma | Pre-clinical | 23 |